Jeena Sikho Lifecare has published six additional clinical case studies in peer-reviewed journals, further expanding its portfolio of evidence-based Ayurvedic research. The disclosures were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on August 18, 2026.

This update follows the company's previous disclosure on August 17, 2026, where it reported seven case studies published in Ayushdhara and the International Research Journal of Ayurveda & Yoga. The latest publications appear in the Academia Journal of Medicine and Prakriti - The International Multidisciplinary Research Journal.

New Research Publications

The newly published studies were authored by medical professionals associated with the company, including Managing Director Manish Grover, senior consultants, and Ayurvedic experts. The research covers a range of conditions, with a notable focus on renal health and reproductive medicine.

The inclusion of multiple studies on kidney disease—covering both chronic and acute phases, as well as specific Ayurvedic concepts like Vrikka Roga and Mutravaha Srotas Dushti—highlights the company's specialized clinical experience in nephrology. Additionally, the study on Vandhyatva (infertility) expands the scope of their documented therapeutic interventions into reproductive health.

Strategic Implications

These publications serve to validate the company’s clinical protocols through peer-reviewed channels. By documenting outcomes for high-prevalence chronic conditions like kidney disease, as well as specific issues like piles and infertility, Jeena Sikho Lifecare reinforces its brand positioning as a provider of specialized, research-backed Ayurvedic care. The continued involvement of the Managing Director in authoring these studies signals strong leadership engagement in the company’s scientific and educational initiatives.

The cumulative effect of publishing 13 case studies within a single day underscores a concerted effort to build a robust body of clinical evidence supporting the company's treatment methodologies.

Jeena Sikho Lifecare reported a robust start to fiscal year 2027, with revenue from operations rising 29% year-on-year (YoY) to ₹22,440 lakh in the first quarter ended June 30, 2026. The Ayurveda healthcare provider posted a 28% YoY increase in profit after taxes (PAT) to ₹6,569 lakh, supported by higher patient footfalls, expanded service networks, and strong momentum in its products business. The company’s earnings conference call, scheduled for August 10, 2026, will provide further management commentary on these results.

The financial performance reflects improving operating leverage and better utilization of existing infrastructure. Revenue grew 4% quarter-on-quarter (QoQ) from ₹21,555 lakh in Q4FY26. Gross profit increased 27% YoY to ₹19,873 lakh, maintaining a gross margin of 89%. The company submitted its investor presentation pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on August 9, 2026.

Operational Highlights

Jeena Sikho Lifecare operates 62 hospitals and 57 clinics across 23 states, with approximately 2,400 operational beds. Inpatient department (IPD) volumes surged 33% YoY, while day care volumes grew 31% YoY to 19,419 patients per day. Outpatient department (OPD) volumes rose 22% YoY. The Panchakarma revenue segment grew 13% YoY, indicating sustained demand for core Ayurvedic treatments.

Business Vertical Performance

The Ayurveda Healthcare Products business delivered 47% YoY growth during the quarter, driven by a broader product portfolio and increasing acceptance of quality-focused Ayurveda offerings. The INJK Water Device, launched in December 2024, emerged as the largest contributor to the product portfolio in Q1FY27. The Services vertical benefited from higher IPD and day care volumes, reinforcing the company’s cross-selling flywheel where medicine buyers visit clinics and clinic patients consume medicines post-treatment.

What the Numbers Show

While revenue growth accelerated to 29% YoY, EBITDA margins contracted by 415 basis points to 41% from 45% in Q1FY26. This divergence suggests that operating expenses, which rose 38% YoY to ₹10,662 lakh, outpaced revenue growth in absolute terms, potentially due to expansion costs or higher marketing spend associated with new facility openings. However, the significant rise in other income (1,212% YoY to ₹1,402 lakh) bolstered the bottom line, contributing to the 28% PAT growth despite the margin compression. Investors should monitor whether operating leverage improves as the 450 beds in pipeline come online, potentially stabilizing margins in subsequent quarters.